Published :
Tables : 45
Figures : 42
Category : Healthcare
No. of Pages : 210
Report Code : HC-U3264
Active Implantable Devices Market is estimated to value at a CAGR of over 6.5% during the forecast period 2022 to 2028. The increased necessity for safer, effective and faster devices is a major driving factor contributing to the growth of the market. Additionally, factors like increased number of patients diagnosed with cardiovascular diseases, rising occurrence of neurological diseases, soaring investments and financial assistance for developing advanced products and a wide range of neurostimulator applications are predicted to drive the market growth further. Furthermore, the rising geriatric population is another factor contributing to the active implantable devices market growth. However, reimbursement policies that are unfavourable to the general population shall hamper the growth of the market substantially. Market Segmentation: By Product • Implantable Cardiac Pacemakers • Implantable Cardioverter Defibrillators o Transvenous Implantable Cardioverter Defibrillators • Biventricular Implantable Cardioverter Defibrillators • Dual-Chamber Implantable Cardioverter Defibrillators • Single-Chamber Implantable Cardioverter Defibrillators o Subcutaneous Implantable Cardioverter Defibrillators • Ventricular Assist Devices • Implantable Heart Monitors/Insertable Loop Recorders • Implantable Hearing Devices • Neurostimulators o Spinal Cord Stimulators o Deep Brain Stimulators o Sacral Nerve Stimulators o Vagus Nerve Stimulators o Gastric Electrical Stimulators By Region North America Europe Asia-Pacific Latin America Middle East and Africa The market is categorised into product and region. The product segment is classified into implantable cardiac pacemakers, cardioverter defibrillators, ventricular assist devices, implantable heart monitors/insertable loop recorders, implantable hearing devices and neurostimulators. The implantable cardioverter defibrillators are predicted to hold the largest active implantable devices market share, and this is due to the rising prevalence of cardiovascular diseases, advancements in the development of implantable devices and increased insistence for these devices in developed nation. For instance, as per the National Institute of Health, over 50% of the deaths related to cardiovascular disorders are caused by sudden cardiac arrests and over 75% of the deaths are caused due to ventricular tachyarrhythmias. Regional Analysis: The North America region is anticipated to lead the market owing to the rising ageing population, increase in the occurrence of appalling diseases, rise in the overall healthcare expenditure and initiation of multiple projects for improving the healthcare infrastructure. The Asia Pacific region, however, is anticipated to grow at a remarkable rate during the forecasted timeframe owing to the rising geriatric population and increased preference towards fast and oily foods leading to obesity. Additionally, increased financial assistance from public and private entities for developing an efficient healthcare infrastructure has propelled the market growth in the region. Competitive Landscape: The prominent market players included are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, LivaNova PLC, Cochlear Limited, MED-EL, Sonova Holding AG, William Demant Holding A/S, Nurotron Biotechnology Co. Ltd. FutureWise Key Takeaways: Growth prospects SWOT analysis Key market trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the global active implantable devices market by product and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
The increased necessity for safer, effective and faster devices is a major driving factor contributing to the growth of the market. Additionally, factors like increased number of patients diagnosed with cardiovascular diseases, rising occurrence of neurological diseases, soaring investments and financial assistance for developing advanced products and a wide range of neurostimulator applications are predicted to drive the market growth further. Furthermore, the rising geriatric population is another factor contributing to the active implantable devices market growth. However, reimbursement policies that are unfavourable to the general population shall hamper the growth of the market substantially.
Market Segmentation:
By Product
• Implantable Cardiac Pacemakers • Implantable Cardioverter Defibrillators o Transvenous Implantable Cardioverter Defibrillators • Biventricular Implantable Cardioverter Defibrillators • Dual-Chamber Implantable Cardioverter Defibrillators • Single-Chamber Implantable Cardioverter Defibrillators o Subcutaneous Implantable Cardioverter Defibrillators • Ventricular Assist Devices • Implantable Heart Monitors/Insertable Loop Recorders • Implantable Hearing Devices • Neurostimulators o Spinal Cord Stimulators o Deep Brain Stimulators o Sacral Nerve Stimulators o Vagus Nerve Stimulators o Gastric Electrical Stimulators
By Region
The market is categorised into product and region. The product segment is classified into implantable cardiac pacemakers, cardioverter defibrillators, ventricular assist devices, implantable heart monitors/insertable loop recorders, implantable hearing devices and neurostimulators. The implantable cardioverter defibrillators are predicted to hold the largest active implantable devices market share, and this is due to the rising prevalence of cardiovascular diseases, advancements in the development of implantable devices and increased insistence for these devices in developed nation. For instance, as per the National Institute of Health, over 50% of the deaths related to cardiovascular disorders are caused by sudden cardiac arrests and over 75% of the deaths are caused due to ventricular tachyarrhythmias.
Regional Analysis:
The North America region is anticipated to lead the market owing to the rising ageing population, increase in the occurrence of appalling diseases, rise in the overall healthcare expenditure and initiation of multiple projects for improving the healthcare infrastructure. The Asia Pacific region, however, is anticipated to grow at a remarkable rate during the forecasted timeframe owing to the rising geriatric population and increased preference towards fast and oily foods leading to obesity. Additionally, increased financial assistance from public and private entities for developing an efficient healthcare infrastructure has propelled the market growth in the region.
Competitive Landscape:
The prominent market players included are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, BIOTRONIK SE & Co. KG, LivaNova PLC, Cochlear Limited, MED-EL, Sonova Holding AG, William Demant Holding A/S, Nurotron Biotechnology Co. Ltd.
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Active Implantable Devices Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Active Implantable Devices Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Active Implantable Devices Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Active Implantable Devices Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Implantable Cardiac Pacemakers 7.2 Implantable Cardioverter Defibrillators 7.2.1 Transvenous Implantable Cardioverter Defibrillators 7.2.1.1 Biventricular Implantable Cardioverter Defibrillators 7.2.1.2 Dual-Chamber Implantable Cardioverter Defibrillators 7.2.1.3 Single-Chamber Implantable Cardioverter Defibrillators 7.2.2 Subcutaneous Implantable Cardioverter Defibrillators 7.3 Ventricular Assist Devices 7.4 Implantable Heart Monitors/Insertable Loop Recorders 7.5 Implantable Hearing Devices 7.6 Neurostimulators 7.6.1 Spinal Cord Stimulators 7.6.2 Deep Brain Stimulators 7.6.3 Sacral Nerve Stimulators 7.6.4 Vagus Nerve Stimulators 7.6.5 Gastric Electrical Stimulators 8. North America Active Implantable Devices Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 8.1. Introduction 8.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 8.2.1. U.S.A 8.2.2. Canada 8.2.3. Mexico 8.3. Market Size (USD Million) Forecast for North America 2022-2028 9. Latin America Active Implantable Devices Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 9.2.1. Brazil 9.2.2. Venezuela 9.2.3. Argentina 9.2.4. Rest of Latin America 9.3. Market Size (USD Million) Forecast for Latin America 2022-2028 10. Europe Active Implantable Devices Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. Germany 10.2.2. U.K 10.2.3. France 10.2.4. Italy 10.2.5. Spain 10.2.6. Russia 10.2.7. Poland 10.2.7. Rest of Europe 10.3. Market Size (USD Million) Forecast for Europe 2022-2028 11. Asia Pacific Active Implantable Devices Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Japan 11.2.2. China 11.2.3. India 11.2.4. Australia and New Zealand 11.2.5. ASEAN 11.2.6. Rest of Asia Pacific 11.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 12. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. GCC 12.2.2. Israel 12.2.3. South Africa 12.2.4. Rest of MEA 12.3. Market Size (USD Million) Forecast for MEA 2022-2028 13. Market Share Analysis and Competitive Landscape 13.1. Global Landscape - Key Players, Revenue and Presence 13.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 13.3. Global Emerging Companies 13.4. North America - Market Share Analysis and Key Regional Players 13.5. Europe - Market Share Analysis and Key Regional Players 13.6. Asia Pacific - Market Share Analysis and Key Regional Players 13.7. Global Key Player - Growth Matrix 14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 14.1. Medtronic plc 14.1.1. Company Overview 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2. Abbott Laboratories 14.2.1. Company Overview 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3. Boston Scientific Corporation 14.3.1. Company Overview 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4. BIOTRONIK SE & Co. KG 14.4.1. Company Overview 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5. LivaNova PLC 14.5.1. Company Overview 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6. Cochlear Limited 14.6.1. Company Overview 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 14.7. MED-EL 14.7.1. Company Overview 14.7.2. Product Portfolio 14.7.3. SWOT Analysis 14.7.4. Financial Overview 14.7.5. Strategic Overview 14.8. Sonova Holding AG 14.8.1. Company Overview 14.8.2. Product Portfolio 14.8.3. SWOT Analysis 14.8.4. Financial Overview 14.8.5. Strategic Overview 14.9. William Demant Holding A/S 14.9.1. Company Overview 14.9.2. Product Portfolio 14.9.3. SWOT Analysis 14.9.4. Financial Overview 14.9.5. Strategic Overview 14.10.Nurotron Biotechnology Co. Ltd. 14.10.1. Company Overview 14.10.2. Product Portfolio 14.10.3. SWOT Analysis 14.10.4. Financial Overview 14.10.5. Strategic Overview 15. Pre and Post COVID-19 Impact 15.1. Positive influence on the healthcare industry 15.2. The financial disruption of the manufacturing sector 15.3. Impact of COVID-19 on emerging companies 15.4. Significant mandates in the healthcare regulations initiated by administrations 15.5. The overall economic slowdown of the developing and developed nations 16. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Active Implantable Devices Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Active Implantable Devices Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Active Implantable Devices Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Active Implantable Devices Market, By Product Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Implantable Cardiac Pacemakers 7.2 Implantable Cardioverter Defibrillators 7.2.1 Transvenous Implantable Cardioverter Defibrillators 7.2.1.1 Biventricular Implantable Cardioverter Defibrillators 7.2.1.2 Dual-Chamber Implantable Cardioverter Defibrillators 7.2.1.3 Single-Chamber Implantable Cardioverter Defibrillators 7.2.2 Subcutaneous Implantable Cardioverter Defibrillators 7.3 Ventricular Assist Devices 7.4 Implantable Heart Monitors/Insertable Loop Recorders 7.5 Implantable Hearing Devices 7.6 Neurostimulators 7.6.1 Spinal Cord Stimulators 7.6.2 Deep Brain Stimulators 7.6.3 Sacral Nerve Stimulators 7.6.4 Vagus Nerve Stimulators 7.6.5 Gastric Electrical Stimulators
8. North America Active Implantable Devices Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 8.1. Introduction 8.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 8.2.1. U.S.A 8.2.2. Canada 8.2.3. Mexico 8.3. Market Size (USD Million) Forecast for North America 2022-2028
9. Latin America Active Implantable Devices Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 9.1. Introduction 9.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 9.2.1. Brazil 9.2.2. Venezuela 9.2.3. Argentina 9.2.4. Rest of Latin America 9.3. Market Size (USD Million) Forecast for Latin America 2022-2028
10. Europe Active Implantable Devices Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 10.1. Introduction 10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 10.2.1. Germany 10.2.2. U.K 10.2.3. France 10.2.4. Italy 10.2.5. Spain 10.2.6. Russia 10.2.7. Poland 10.2.7. Rest of Europe 10.3. Market Size (USD Million) Forecast for Europe 2022-2028
11. Asia Pacific Active Implantable Devices Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. Japan 11.2.2. China 11.2.3. India 11.2.4. Australia and New Zealand 11.2.5. ASEAN 11.2.6. Rest of Asia Pacific 11.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
12. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. GCC 12.2.2. Israel 12.2.3. South Africa 12.2.4. Rest of MEA 12.3. Market Size (USD Million) Forecast for MEA 2022-2028
13. Market Share Analysis and Competitive Landscape 13.1. Global Landscape - Key Players, Revenue and Presence 13.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 13.3. Global Emerging Companies 13.4. North America - Market Share Analysis and Key Regional Players 13.5. Europe - Market Share Analysis and Key Regional Players 13.6. Asia Pacific - Market Share Analysis and Key Regional Players 13.7. Global Key Player - Growth Matrix
14. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 14.1. Medtronic plc 14.1.1. Company Overview 14.1.2. Product Portfolio 14.1.3. SWOT Analysis 14.1.4. Financial Overview 14.1.5. Strategic Overview 14.2. Abbott Laboratories 14.2.1. Company Overview 14.2.2. Product Portfolio 14.2.3. SWOT Analysis 14.2.4. Financial Overview 14.2.5. Strategic Overview 14.3. Boston Scientific Corporation 14.3.1. Company Overview 14.3.2. Product Portfolio 14.3.3. SWOT Analysis 14.3.4. Financial Overview 14.3.5. Strategic Overview 14.4. BIOTRONIK SE & Co. KG 14.4.1. Company Overview 14.4.2. Product Portfolio 14.4.3. SWOT Analysis 14.4.4. Financial Overview 14.4.5. Strategic Overview 14.5. LivaNova PLC 14.5.1. Company Overview 14.5.2. Product Portfolio 14.5.3. SWOT Analysis 14.5.4. Financial Overview 14.5.5. Strategic Overview 14.6. Cochlear Limited 14.6.1. Company Overview 14.6.2. Product Portfolio 14.6.3. SWOT Analysis 14.6.4. Financial Overview 14.6.5. Strategic Overview 14.7. MED-EL 14.7.1. Company Overview 14.7.2. Product Portfolio 14.7.3. SWOT Analysis 14.7.4. Financial Overview 14.7.5. Strategic Overview 14.8. Sonova Holding AG 14.8.1. Company Overview 14.8.2. Product Portfolio 14.8.3. SWOT Analysis 14.8.4. Financial Overview 14.8.5. Strategic Overview 14.9. William Demant Holding A/S 14.9.1. Company Overview 14.9.2. Product Portfolio 14.9.3. SWOT Analysis 14.9.4. Financial Overview 14.9.5. Strategic Overview 14.10.Nurotron Biotechnology Co. Ltd. 14.10.1. Company Overview 14.10.2. Product Portfolio 14.10.3. SWOT Analysis 14.10.4. Financial Overview 14.10.5. Strategic Overview
15. Pre and Post COVID-19 Impact 15.1. Positive influence on the healthcare industry 15.2. The financial disruption of the manufacturing sector 15.3. Impact of COVID-19 on emerging companies 15.4. Significant mandates in the healthcare regulations initiated by administrations 15.5. The overall economic slowdown of the developing and developed nations
16. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics